Table 2.
Medications of Interest Used Within 30 Days Prior to Screening Visit.
| n (%) | Taking RAAS Inhibitors (n = 67) | Not Taking RAAS Inhibitors (n = 45) | Total (N = 112) |
|---|---|---|---|
| Non-RAAS inhibitor diuretica | 24 (36) | 16 (36) | 40 (36) |
| Insulin | 26 (39) | 15 (33) | 41 (37) |
| β-blocker | 30 (45) | 28 (62) | 58 (52) |
| β-agonistb | 4 (6) | 4 (9) | 8 (7) |
| NSAID (systemic) | |||
| Ibuprofen | 2 (3) | 1 (2) | 3 (3) |
| Aspirin | 23 (34) | 21 (47) | 44 (39) |
| Coxib | 1 (2) | 0 | 1 (<1) |
| Lactulose | 0 | 1 (2) | 1 (<1) |
| Sodium polystyrene sulfonatec | 1 (2) | 2 (4) | 3 (3) |
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; RAAS, renin–angiotensin–aldosterone system.
a All non-RAAS inhibitor diuretics were potassium-wasting.
b β-agonists given for obstructive airway.
c Sodium polystyrene sulfonate not allowed within 7 days prior to screening.